• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Thera (NQ: AXSM )

    72.86 +0.62 (+0.87%)
    Streaming Delayed Price Updated: 10:44 AM EDT, Jun 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Axsome Thera

    < Previous 1 2
    ...
    8 9 10 11 12 13 14 15 Next >
    Better Buy: Moderna vs. Axsome Therapeutics
    Both of these biotechs offer exciting future prospects. 
    Via The Motley Fool
    If You Invested $5,000 in Axsome Therapeutics in 2019, This Is How Much You Would Have Today
    Could the stock keep performing? 
    Via The Motley Fool
    Jim Cramer On This Industrial Stock: 'You Don't Know What's In It'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Sociedad Quimica y Minera de Chile (NYSE: SQM) as "fertilizer’s in short supply and so is lithium." 
    Via Benzinga
    3 Stocks Savvy Investors Are Buying Hand Over Fist
    These high-flying stocks are defying the bear market. 
    Via The Motley Fool
    Axsome Therapeutics' Sunosi Improves Cognitive Function In Patients With Sleep Disorder
    Via Benzinga
    8 Analysts Have This to Say About Axsome Therapeutics
    Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: 
    Via Benzinga
    Mizuho Bolsters Price Target By 55% On This Migraine Stock
    Via Benzinga
    Analyst Ratings for Axsome Therapeutics
    Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings: 
    Via Benzinga
    Expert Ratings for Axsome Therapeutics
    Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings: 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
    We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
    Via Talk Markets
    7 Top-Rated Biotech Stocks to Buy for Q4
    A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
    Via InvestorPlace
    Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
    President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
    Via InvestorPlace
    Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says
    Via Benzinga
    Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
    Via Benzinga
    Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Axsome Therapeutics Commences Late-Stage Migraine Study
    Axsome Therapeutics (NASDAQ: AXSM) has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine. 
    Via Benzinga
    Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
    After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
    Via Benzinga
    HC Wainwright Boosts Price Target On This Stock By 167%, Plus B of A Securities Predicts $40 For This Online Travel Stock
    HC Wainwright & Co. raised the price target for Rockwell Medical, Inc. (NASDAQ: RMTI) from $3 to $8. Rockwell Medical shares rose 0.7% to close at $1.42 on Monday. 
    Via Benzinga
    $1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today
    Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 57.38% on an annualized basis producing an average annual return of 67.54%. Currently, Axsome Therapeutics has a... 
    Via Benzinga
    10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
    These names are benefitting from M&A, clinical data and promising regulatory actions. 
    Via Investor's Business Daily
    AMC Entertainment Price Target Cut By This Analyst, Plus DA Davidson Predicts $318 For Estée Lauder
    DA Davidson cut the price target for The Estée Lauder Companies Inc. (NYSE: EL) from $342 to $318. Estée Lauder shares fell 0.4% to $264.29 in pre-market trading. 
    Via Benzinga
    Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
    UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. 
    Via Benzinga
    Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
    Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. 
    Via Benzinga
    Stocks That Made New Highs On Friday, Aug. 19
    On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
    Via Talk Markets
    Recap Of Friday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    S&P 500 Down More Than 1%; Bed Bath & Beyond Shares Plummet
    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 250 points on Friday. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
      
    Via Benzinga
    Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression Drug
    Axsome's drug targets a neurotransmitter believed to play a role in depression. 
    Via Investor's Business Daily
    Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
    Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. 
    Via Benzinga
    < Previous 1 2
    ...
    8 9 10 11 12 13 14 15 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.